Rocuronium bromide

Additional information:
Rocuronium Bromide is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia to facilitate endotracheal intubation by providing skeletal muscle relaxation. It is used for both standard and rapid sequence induction (RSI).{{Mifanertinib dimaleate} MedChemExpress|{Mifanertinib dimaleate} Protein Tyrosine Kinase/RTK|{Mifanertinib dimaleate} Protocol|{Mifanertinib dimaleate} Description|{Mifanertinib dimaleate} custom synthesis|{Mifanertinib dimaleate} Epigenetics} Rocuronium bromide competitively binds to the nicotinic receptor at the motor end plate, and antagonizes acetylcholine binding.|Product information|CAS Number: 119302-91-9|Molecular Weight: 609.68|Formula: C32H53BrN2O4|Synonym:|Zemuron|Rocuronium (Bromide)|Esmeron|UNII-I65MW4OFHZ|Esmerone|ORG 9426|ORG-9426|Related CAS Number:|143558-00-3 (Rocuronium cation)|Chemical Name: [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17R)-3-hydroxy-10, 13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate;bromide|Smiles: [Br-].CC12CCC3C(CCC4CC(O)C(CC43C)N3CCOCC3)C1CC(C2OC(C)=O)[N+]1(CC=C)CCCC1|InChiKey: OYTJKRAYGYRUJK-UHFFFAOYSA-M|InChi: InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 122 mg/mL(200.1 mM). Water: 122 mg/mL(200.1 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Rocuronium bromide (RB), an aminosteroid type neuromuscular blocking agent, acts by reducing or inhibiting the depolarising effect of acetylcholine on the terminal disc of the muscle cell. Rocuronium interacts with human liver microsomal cytochromes P450 (CYP) by binding to the substrate site.{{9-cis-Retinoic acid} site|{9-cis-Retinoic acid} RAR/RXR|{9-cis-Retinoic acid} Epigenetics|{9-cis-Retinoic acid} Biological Activity|{9-cis-Retinoic acid} In Vitro|{9-cis-Retinoic acid} custom synthesis} Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively.PMID:22664133 |In Vivo:|Rocuronium is an ideal muscle relaxant with a rapid onset, intermediate duration of action, nondepolarizing properties and lack of cardiovascular side effects. Rocuronium produces a dose-dependent duration of neuromuscular blockade in isoflurane anesthetized horses. Rocuronium bromide, is a relatively low potency, intermediate-acting agent with a rapid onset time of 98 seconds in dogs. Rocuronium is an effective nondepolarizing muscle relaxant in the cat under the clinical conditions of this study. Rocuronium has a rapid onset, a short duration of action. Rocuronium (0.6 mg/kg) results in a significant increase in heart rate one min after IV administration in the dog. Rocuronium (0.3 mg/kg and 0.6 mg/kg) produce a reliable neuromuscular block of 23–32 min duration, respectively. Rocuronium bromide paralyzes the internal laryngeal muscles keeping the vocal cords in an intermediate position (paramedial) 60 seconds after being administered in cats.|References:|Auer U, et al. Vet Ophthalmol,?011, 14(4), 244-247.Anzenbacherova E, et al. J Pharmacol Sci,?015, 127(2), 190-195.Zan U, et al. Cytotechnology,?011, 63(3), 239-245.Products are for research use only. Not for human use.|